Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)

Clinicaltrials.gov identifier:
NCT04497844

Treatment
Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene

Differences in Family Communication about Positive Genetic Test Results Between Indian, Chinese, and Filipino Americans

Surveys, Registries, Interviews
Interview for Indian, Chinese or Filipino Americans with a mutation in BRCA1, BRCA2, ATM, CHEK2, PALB2 or other gene linked to breast or ovarian cancer risk

Combination Drugs for Treating Metastatic Castration-resistant Prostate Cancer with Tumor Mutation the Affect DNA Repair

Clinicaltrials.gov identifier:
NCT03012321

Treatment
Treatment study for men with metastatic castration-resistant prostate cancer

PARP inhibitor (niraparib) in patients with inherited or tumor PALB2 mutations in advanced solid tumors (PAVO)

Clinicaltrials.gov identifier:
NCT05169437

Treatment
Any advanced or metastatic solid tumor except ovarian or prostate

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05252390

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

Physical Activity Promotion for Breast and Endometrial Cancer Survivors

Clinicaltrials.gov identifier:
NCT04262180

Quality of Life
Exercise study for breast or endometrial cancer survivors

Studying the Medication Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis

Clinicaltrials.gov identifier:
NCT03317392

Treatment
People with castration-resistant prostate cancer with bone spread

Denosumab for Preventing Breast Cancer in Women with a BRCA1 Inherited Mutation (BRCA-P)

Clinicaltrials.gov identifier:
NCT04711109

Prevention
Prevention study enrolling women ages 25-55 with a BRCA1 mutation

Abiraterone/Prednisone and Olaparib Alone or In Combination for Treatment of Metastatic Castration-Resistant Prostate Cancer With Mutations Related to DNA Repair

Clinicaltrials.gov identifier:
NCT03012321

Treatment
Men with mCRPC with an inherited mutation or a tumor mutation in a DNA damage repair gene

Research Opportunity for Previvors and their Romantic Partners

Surveys, Registries, Interviews
Interview for people with inherited mutations who had risk-reducing mastectomy and their partners

TALAPRO-3: A Clinical Trial in Men with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and DNA Damage Repair (DDR) Gene Alteration

Clinicaltrials.gov identifier:
NCT04821622

Treatment
Metastatic castration-sensitive prostate cancer

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

Clinicaltrials.gov identifier:
NCT05129605

Prevention
People at high risk for prostate cancer due to an inherited mutation

Survey about Endometrial Cancer Risk and Risk-Reducing Surgery for Women with a BRCA1/2 Mutation or Mutation in the Family

Surveys, Registries, Interviews
Women with a BRCA mutation or from a family with a BRCA mutation

Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult Breast Cancer Survivors

Clinicaltrials.gov identifier:
NCT04906200

Quality of Life
Women diagnosed with breast cancer between the ages of 15-39

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women

Clinicaltrials.gov identifier:
NCT05287451

Prevention
Prevention study for women at high risk for ovarian cancer

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

Clinicaltrials.gov identifier:
NCT03462342

Treatment
Recurrent ovarian cancer

BRCA 1 and 2: Interviews on Genetic Testing and Individual Experiences

Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing

UCLA Research Study: Zoom Interviews to Learn from Asian Americans Living with Metastatic Cancer

Surveys, Registries, Interviews
Asian Americans with metastatic cancer of any type

EnergyPoints: A Mobile App Guiding Use of Acupressure for Cancer-related Fatigue and Sleep Disturbances

Quality of Life
Anyone diagnosed with cancer experiencing fatigue

A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People with Advanced Pancreatic Cancer and BRCA Mutations

Clinicaltrials.gov identifier:
NCT04150042

Treatment
Advanced pancreatic cancer in people with a BRCA1 or BRCA2 mutation

Metastatic Pancreatic Cancer in US

Surveys, Registries, Interviews
People with metastatic pancreatic cancer and their caregivers

Interviews for people with a genetic test result that was later reclassified

Surveys, Registries, Interviews
People with a genetic test result that was later reclassified

Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer (AVPC)

Clinicaltrials.gov identifier:
NCT04592237

Treatment
Treatment in people with aggressive metastatic prostate cancer

All of Us Research Program

Surveys, Registries, Interviews
Anyone age 18 or over

Studying Crowdfunding for Cancer

Surveys, Registries, Interviews
Cancer survivors who have used crowdfunding to help cover cancer-related costs

RESTORE: A virtual study comparing 2 digital apps to improve mental and physical well-being of patients with stage I – 3 cancer

Clinicaltrials.gov identifier:
NCT05227898

Quality of Life
People with stage 1-3 cancer

Treating Early-Stage BRCA, or PALB2-Associated Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab)

Clinicaltrials.gov identifier:
NCT04584255

Treatment
Early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)

Clinicaltrials.gov identifier:
NCT04194554

Treatment
Newly diagnosed prostate cancer grade group 3-5

Interview Study: Exploring Gender Diverse Experiences of Hereditary Cancer Risk

Surveys, Registries, Interviews
People with elevated cancer risk who identify as trans* or nonbinary

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

Clinicaltrials.gov identifier:
NCT04644068

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer

Interview about Hispanic/Latino Community Experiences Accessing Genetic Testing for Hereditary Cancer Risk

Surveys, Registries, Interviews
Hispanic/Latino people with a personal diagnosis of cancer or a family history of cancer

Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)

Clinicaltrials.gov identifier:
NCT04497116

Treatment
Advanced solid tumors

Screening for Cancer DNA in the Blood after Treatment for Early-Stage TNBC and/or a BRCA Mutation; Followed by Study Comparing Niraparib with Placebo for People with Cancer DNA found in their Blood (ZEST)

Clinicaltrials.gov identifier:
NCT04915755

Treatment
Early-stage TNBC or early-stage breast cancer with a BRCA mutation

ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer

Clinicaltrials.gov identifier:
NCT04267939

Treatment
Advanced ovarian cancer or other solid tumors

Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed

Clinicaltrials.gov identifier:
NCT03231891

Surveys, Registries, Interviews
People with an inherited mutation or cancer in the family

Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation

Clinicaltrials.gov identifier:
NCT04548752

Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation

Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer

Clinicaltrials.gov identifier:
NCT04895722

Treatment
Stage 4 colorectal cancer

Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Colorectal Cancer Survivors

Clinicaltrials.gov identifier:
NCT05056077

Quality of Life
Nonmetastatic colon or rectal cancer

A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors

Clinicaltrials.gov identifier:
NCT04991480

Treatment
Advanced solid tumors

Survey: How Willing are You to Participate in Different Types of Clinical Trials for the Prevention of Breast Cancer?

Surveys, Registries, Interviews

Retifanlimab Alone or with Other Agents for Advanced Endometrial Cancer that Progressed with Platinum

Clinicaltrials.gov identifier:
NCT04463771

Treatment
Advanced endometrial cancer

Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation

Clinicaltrials.gov identifier:
NCT04367675

Prevention
People with a BRCA1 or BRCA2 mutation

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Clinicaltrials.gov identifier:
NCT04030559

Treatment
High-risk localized prostate cancer

Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

Clinicaltrials.gov identifier:
NCT04657068

Treatment
Advanced solid tumors

Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Chemotherapy and Rucaparib

Clinicaltrials.gov identifier:
NCT03337087

Treatment
Metastatic colorectal, pancreatic, gastroesophageal or biliary tract cancer

CYH33 in Combination With Olaparib in Patients With Advanced Solid Tumors and DNA Damage Repair Mutations

Clinicaltrials.gov identifier:
NCT04586335

Treatment
Advanced solid tumors

Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor

Clinicaltrials.gov identifier:
NCT03607890

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

Understanding the Experiences of Black Women after Cancer Genetic Testing

Surveys, Registries, Interviews
Black women who have tested positive for an inherited mutation

Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome

Clinicaltrials.gov identifier:
NCT04379999

Prevention

Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer

Clinicaltrials.gov identifier:
NCT03685331

Treatment

Men at High Genetic Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT03805919

Prevention

Fear of Recurrence, Adversity, and Pain

Surveys, Registries, Interviews

Blood Markers of Early Pancreas Cancer

Clinicaltrials.gov identifier:
NCT03568630

Prevention

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

Clinicaltrials.gov identifier:
NCT04251052

Prevention

Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab

Clinicaltrials.gov identifier:
NCT04493060

Treatment

AMPLIFY: a new online weight loss study specifically for cancer survivors!

Clinicaltrials.gov identifier:
NCT04000880

Quality of Life

Developing a Test for the Detection of Ovarian Cancer

Clinicaltrials.gov identifier:
NCT04794322

Prevention

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Clinicaltrials.gov identifier:
NCT04995198

Surveys, Registries, Interviews

Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study)

Clinicaltrials.gov identifier:
NCT02997228

Treatment

TALAVE: Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Clinicaltrials.gov identifier:
NCT03964532

Treatment

COVID-19 Breast Cancer Care Survey

Surveys, Registries, Interviews

Screening for Pancreatic Cancer in Patients with an Inherited BRCA1, BRCA2, PALB2 or ATM Mutation

Clinicaltrials.gov identifier:
NCT02478892

Prevention

Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

Clinicaltrials.gov identifier:
NCT03831698

Prevention

Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation

Clinicaltrials.gov identifier:
NCT04858334

Treatment

Research Study to Help Improve Family Communication About Inherited BRCA1 or BRCA2 Mutations

Prevention

Phase 1 Study of Oral Drug PMD-026 in People With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

Clinicaltrials.gov identifier:
NCT04115306

Treatment

Addition of Pembrolizumab to Radiation Treatment for Newly Diagnosed Early Stage MSI-High Endometrial Cancer

Clinicaltrials.gov identifier:
NCT04214067

Treatment

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Clinicaltrials.gov identifier:
NCT04042831

Treatment

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families

Prevention

Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (CheckMate 8HW)

Clinicaltrials.gov identifier:
NCT04008030

Treatment
People with metastatic colorectal cancer that is MSI-High

Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

Clinicaltrials.gov identifier:
NCT04666740

Treatment

PARP Inhibitor for Metastatic Prostate Cancer With DNA Repair Defects

Clinicaltrials.gov identifier:
NCT03012321

Treatment

Mobile Mindfulness Meditation Intervention to Improve Neuropathy in Cancer Survivors

Clinicaltrials.gov identifier:
NCT03581357

Quality of Life

Parenting Adolescent-Aged Children While Managing a Parental Cancer Diagnosis – Share Your Story

Surveys, Registries, Interviews

Mobile Mindfulness Meditation Intervention for Cancer Survivors

Clinicaltrials.gov identifier:
NCT03581357

Quality of Life

A Survey on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation

Surveys, Registries, Interviews

Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer

Clinicaltrials.gov identifier:
NCT0823654

Olaparib Expanded - Treating Metastatic Breast Cancer in People without gBRCA Mutations

Clinicaltrials.gov identifier:
NCT03344965

Treatment

The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

Surveys, Registries, Interviews

Diagnosis of Breast Cancer in Young Women - Share Your Story

Surveys, Registries, Interviews

Talazoparib for people with metastatic breast cancer who have acquired (somatic) BRCA mutations

Clinicaltrials.gov identifier:
NCT03990896

Treatment

A Study of Nivolumab in Selected Uterine Cancer Patients

Clinicaltrials.gov identifier:
NCT03241745

Treatment

A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients (E-Reach)

Clinicaltrials.gov identifier:
NCT04353973

Treatment

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Clinicaltrials.gov identifier:
NCT02912559

Treatment

Genetic Testing for Men with Metastatic Prostate Cancer (GENTleMEN Study)

Clinicaltrials.gov identifier:
NCT03503097

Treatment

Metastatic Prostate Cancer Project

Surveys, Registries, Interviews

The Metastatic Breast Cancer Project

Surveys, Registries, Interviews

Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth

Clinicaltrials.gov identifier:
NCT03327103

Quality of Life

Pancreatic Cancer Screening Study for High Risk People

Clinicaltrials.gov identifier:
NCT03250078

Prevention

Denosumab and Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

Clinicaltrials.gov identifier:
NCT04067726

Prevention

Connect My Variant

Surveys, Registries, Interviews

Study for People with Unexpected Genetic Results

Clinicaltrials.gov identifier:
NCT02595957

Prevention

Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job

Clinicaltrials.gov identifier:
NCT03572374

Quality of Life

Breast Cancer Treatment in Women with PALB2 Mutations

Surveys, Registries, Interviews

ELLIE's Project

Quality of Life

INTERVAL: INTense Exercise foR surVivAL in Men With Metastatic Prostate Cancer

Clinicaltrials.gov identifier:
NCT02730338

Quality of Life

RADCOMP: A Study at the Heart of Breast Cancer Treatment

Clinicaltrials.gov identifier:
NCT02603341

Treatment

Identification and Analysis of Families With Genetic Susceptibility To Cancer Registry

Surveys, Registries, Interviews

Find My Variant

Surveys, Registries, Interviews

Pancreatic Cancer Early Detection

Clinicaltrials.gov identifier:
NCT02206360

Prevention

WISDOM Study

Clinicaltrials.gov identifier:
NCT02620852

Prevention

PROMPT

Clinicaltrials.gov identifier:
NCT02665195

Surveys, Registries, Interviews

Talazoparib Beyond BRCA (TBB) Trial

Clinicaltrials.gov identifier:
NCT02401347

Treatment